Acute non-myelosuppressive complications of systemic anticancer therapy

D Rea - Clinical medicine, 2008 - ncbi.nlm.nih.gov
Allopurinol inhibits xanthine oxidase conversion of xanthene to urate and should be initiated
if allopurinol was not used as prophylaxis. Rasburicase is a recombinant urate oxidase and …

Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy?

G Wolf, S Hegewisch-Becker, DK Hossfeld… - American Journal of …, 1999 - Elsevier
Hyperuricemia is a common finding in patients with malignant diseases. Chemotherapy can
induce life-threatening tumor lysis syndrome with severe hyperuricemia, other metabolic …

Advances in the management of malignancy-associated hyperuricaemia

HH Mahmoud, G Leverger, C Patte, E Harvey… - British Journal of …, 1998 - nature.com
Acute tumour lysis syndrome (ATLS) is a metabolic derangement (hyperuricaemia,
hyperphosphataemia, hyperkalaemia and hypocalcaemia) associated with …

Hyperuricemia in patients with cancer

RC Ribeiro, CH Pui - American Journal of Cancer, 2002 - Springer
Hyperuricemia is a common early complication in patients with hematological malignancies
treated with intensive chemotherapy. It results from the breakdown of nuclear proteins …

Allopurinol: intravenous use for prevention and treatment of hyperuricemia

RV Smalley, A Guaspari, S Haase-Statz… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: To tabulate data obtained over a 21-year period to determine the efficacy and
safety of an intravenous (IV) allopurinol preparation. PATIENTS AND METHODS: IV …

Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol

PR Band, DS Silverberg, JF Henderson… - … England Journal of …, 1970 - Mass Medical Soc
ALLOPURINOL is an agent of proved value for the treatment of hyperuricemic and
hyperuricosuric states. 1, 2 Both allopurinol and its principal metabolic product, oxypurinol …

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

S Trifilio, M Tallman, S Singhal, L Gordon, A Evens… - 2004 - ashpublications.org
Hyperuricemia is a feature of tumor lysis syndrome (TLS), and is treated with hydration, urine
alkalinization, and allopurinol. Allopurinol inhibits the conversion of hypoxanthine to …

[CITATION][C] The status of allopurinol in the management of tumor lysis syndrome: a clinical review.

F Hagemeister, A Huen - Cancer Journal (Sudbury, Mass.), 2005 - europepmc.org
The status of allopurinol in the management of tumor lysis syndrome: a clinical review. - Abstract
- Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002

PM Navolanic, CH Pui, RA Larson, MR Bishop… - Leukemia, 2003 - nature.com
Renal precipitation of uric acid associated with tumor lysis syndrome (TLS) is a major
complication in the management of leukemia, lymphoma, and other drug-sensitive cancers …

Role of iv allopurinol and rasburicase in tumor lysis syndrome

MT Holdsworth, P Nguyen - American journal of health-system …, 2003 - academic.oup.com
The role of iv allopurinol and rasburicase in tumor lysis syndrome (TLS) is described. The
current standard management for TLS consists of oral allopurinol in conjunction with iv …